口服司美格鲁肽与高危2型糖尿病的心血管结局
SOUL试验为双盲、安慰剂对照、事件驱动、优效性试验,纳入9650例≥50岁、糖化血红蛋白6.5%–10.0%、已知动脉粥样硬化性心血管病或慢性肾病(或两者兼有)的2型糖尿病患者,随机接受每日一次口服司美格鲁肽(最大剂量14 mg)或安慰剂,均加标准治疗。中位随访49.5个月。主要结局(心血管原因死亡、非致死性心肌梗死或非致死性卒中复合终点)在口服司美格鲁肽组发生579/4825例(12.0%;发生率3.1例/100人年),安慰剂组668/4825例(13.8%;3.7例/100人年),HR 0.86(95%CI 0.77–0.96;P=0.006)。确证性次要结局(包括五点复合肾脏疾病事件)两组无显著差异。严重不良事件发生率口服司美格鲁肽组47.9%、安慰剂组50.3%;胃肠道疾病发生率分别为5.0%和4.4%。
要点
- 主要不良心血管事件:口服司美格鲁肽组579/4825例(12.0%,3.1例/100人年)vs 安慰剂组668/4825例(13.8%,3.7例/100人年),HR 0.86(95%CI 0.77–0.96;P=0.006)。
- 确证性次要结局(含五点复合肾脏疾病事件)两组无显著差异。
- 严重不良事件发生率口服司美格鲁肽组47.9% vs 安慰剂组50.3%;胃肠道疾病发生率5.0% vs 4.4%。
- 适用人群为≥50岁、糖化血红蛋白6.5%–10.0%、合并动脉粥样硬化性心血管病或慢性肾病(或两者兼有)的2型糖尿病患者,在标准治疗基础上每日一次口服司美格鲁肽最大剂量14 mg。
- 中位随访49.5个月(均值47.5±10.9个月)观察到上述心血管获益。
适用人群与场景
- ≥50岁、2型糖尿病、糖化血红蛋白6.5%–10.0%,且已知动脉粥样硬化性心血管病、慢性肾病或两者兼有的患者;在标准治疗基础上随机接受每日一次口服司美格鲁肽(最大剂量14 mg)或安慰剂。
处置流程与药物剂量
- 在标准治疗基础上,每日一次口服司美格鲁肽,最大剂量14 mg;对照为安慰剂。
研究设计与关键结果
- 双盲、安慰剂对照、事件驱动、优效性试验,随机9650例,口服司美格鲁肽组4825例、安慰剂组4825例;均值随访47.5±10.9个月,中位随访49.5个月。
- 主要结局(心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点,时间至首次事件分析):口服司美格鲁肽组579/4825例(12.0%;发生率3.1例/100人年)vs 安慰剂组668/4825例(13.8%;发生率3.7例/100人年),HR 0.86(95%CI 0.77–0.96;P=0.006)。
- 确证性次要结局(包括五点复合肾脏疾病事件)两组无显著差异。
- 严重不良事件发生率:口服司美格鲁肽组47.9% vs 安慰剂组50.3%;胃肠道疾病发生率:口服司美格鲁肽组5.0% vs 安慰剂组4.4%。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照、事件驱动、优效性随机对照试验(SOUL,ClinicalTrials.gov NCT03914326;由Novo Nordisk资助)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在合并动脉粥样硬化性心血管病、慢性肾病或两者的2型糖尿病患者中,口服司美格鲁肽与主要不良心血管事件风险显著低于安慰剂相关,且未增加严重不良事件发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed.
METHODS: In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome).
RESULTS: Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively.
CONCLUSIONS: Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).
参考来源
- McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. PMID: 40162642. doi:10.1056/NEJMoa2501006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。